{
  "id": "adv_mhgap#risk_safety_5ec7c815",
  "content": "no clear evidence of differences between y More trials comparing second-generation LAI\nantipsychotics), but data were sparse. antipsychotics head-to-head are needed.\ny All LAIs showed less discontinuation for any reason y More trials comparing first-generation\ncompared with placebo. antipsychotics and second-generation\n– Sedation: Olanzapine LAI, paliperidone LAI, antipsychotics are needed.\nhaloperidol LAI and aripiprazole LAI increased\nImplementation considerations\nthe risk for sedation compared with placebo\ny With LAIs, compliance of people living with psychotic\nin various degrees; the 95% CIs indicated no\ndisorders with treatment plans can be improved.\nsignificant effect.\ny Acquisition costs of LAIs can differ substantially and\n– Use of anticholinergic medicine: All LAIs were\nalso throughout the world.\nassociated with the use of anticholinergic\nmedicine. y People living with long term psychotic disorders\nshould be involved in medicine choice in a\n92\n3. Recommendations\nsupported decision-making process, without y The dosing interval should be considered based\ncoercion and in line with human rights instruments. on the LAIs prescribed and their recommended\ny Treatment with antipsychotic medicines should be intervals. For further information on duration of\ncombined with psychosocial interventions (see other treatment, please refer to recommendation PSY2.\nrecommendations in this module – namely PSY11).",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "referral",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Risk Safety no clear evidence of differences between y More trials comparing second-generation LAI\nantipsychotics), but data were sparse. antipsychotics head-to-head are needed.\ny All LAIs showed less discontinuation for any reason y More trials comparing first-generation\ncompared with placebo. antipsychotics and second-generation\n– Sedation: Olanzapine LAI, paliperidone LAI, antipsychotics are needed.\nhaloperidol LAI and aripiprazole LAI increased\nImplementation considerations\nthe risk for sedation compared with placebo\ny With LAIs, compliance of people living with psychotic\nin various degrees; the 95% CIs indicated no\ndisorders with treatment plans can be improved.\nsignificant effect.\ny Acquisition costs of LAIs can differ substantially and\n– Use of anticholinergic medicine: All LAIs were\nalso throughout the world.\nassociated with the use of anticholinergic\nmedicine. y People living with long term psychotic disorders\nshould be involved in medicine choice in a\n92\n3. Recommendations\nsupported decision-making process, without y The dosing interval should be considered based\ncoercion and in line with human rights instruments. on the LAIs prescribed and their recommended\ny Treatment with antipsychotic medicines should be intervals. For further information on duration of\ncombined with psychosocial interventions (see other treatment, please refer to recommendation PSY2.\nrecommendations in this module – namely PSY11). No clear evidence of differences between y more trials comparing second-generation lai\nantipsychotics), but data were sparse. antipsychotics head-to-head are needed."
}